<a href="https://www.fiercebiotech.com/biotech/windward-catches-165m-breeze-fuel-long-acting-tslp-ambitions" hreflang="en">Windward catches $165M breeze to fuel long-acting TSLP ambitions</a>
Windward Bio has secured $165 million in crossover financing to advance its long-acting anti-TSLP antibody, WIN378, into phase 3 trials, aiming to differentiate itself in the competitive respiratory market with a twice-yearly dosing schedule. The funding will also support the development of its bispecific candidate, WIN027, for various respiratory and dermatological conditions.
Windward Bio's recent $165 million crossover financing, led by OrbiMed and including new investors such as RA Capital Management and Sanofi Ventures, signals strong interest in its long-acting anti-TSLP therapies, which are poised to be key differentiators in the competitive respiratory market with a twice-yearly dosing schedule. This funding round highlights a significant investment opportunity in the development of next-generation immunology therapies, particularly as Windward accelerates its phase 3 trials for asthma and initiates new studies for chronic obstructive pulmonary disease and other indications.